Cargando…
Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed
Rapamycin has been used topically to treat facial angiofibromas associated with tuberous sclerosis for more than a decade. In the absence of a commercial form, a large number of formulations have been clinically tested. However, given the great heterogeneity of these studies, particularly with regar...
Autores principales: | Le Guyader, Guillaume, Do, Bernard, Vieillard, Victoire, Andrieux, Karine, Paul, Muriel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7694993/ https://www.ncbi.nlm.nih.gov/pubmed/33171735 http://dx.doi.org/10.3390/pharmaceutics12111060 |
Ejemplares similares
-
Topical rapamycin (sirolimus) for facial angiofibromas
por: Madke, Bhushan
Publicado: (2013) -
Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017) -
Use of Topical Rapamycin in Facial Angiofibromas in Indian Skin Type
por: Viswanath, Vishalakshi, et al.
Publicado: (2016) -
Facial Angiofibromas of Tuberous Sclerosis Treated with Topical Sirolimus in an Indian Patient
por: Vasani, Resham J
Publicado: (2015) -
Co-Encapsulation of Fisetin and Cisplatin into Liposomes for Glioma Therapy: From Formulation to Cell Evaluation
por: Renault-Mahieux, Morgane, et al.
Publicado: (2021)